GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » 14-Day RSI

Protagonist Therapeutics (Protagonist Therapeutics) 14-Day RSI : 60.77 (As of May. 11, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-11), Protagonist Therapeutics's 14-Day RSI is 60.77.

The industry rank for Protagonist Therapeutics's 14-Day RSI or its related term are showing as below:

PTGX's 14-Day RSI is ranked worse than
86.22% of 1575 companies
in the Biotechnology industry
Industry Median: 47.39 vs PTGX: 60.77

Competitive Comparison of Protagonist Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Protagonist Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's 14-Day RSI falls into.



Protagonist Therapeutics  (NAS:PTGX) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protagonist Therapeutics  (NAS:PTGX) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Protagonist Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics (Protagonist Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Harold E Selick director
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035